申请人:Aquinox Pharmaceuticals (Canada) Inc.
公开号:US10272081B2
公开(公告)日:2019-04-30
Compounds of formula (I):
where
n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
式(I)化合物:
其中
n、R1、R4a、R4b、R5、R7 和 R8 在本文中定义,或其药学上可接受的盐在本文中描述。所公开的化合物具有 SHIP1 调节剂的活性,因此可用于治疗 SHIP1 调节所带来的各种疾病、失调或病症中的任何一种。此外,还公开了由式(I)化合物与药学上可接受的载体或稀释剂组合而成的组合物,以及通过向有需要的动物施用此类化合物来调节 SHIP1 的方法。